Streamlined Assay Improves Prenatal Detection of Alpha-Thalassemia
|
By LabMedica International staff writers Posted on 09 Jun 2020 |

Image: The Bio-Rad CFX96 Real-Time PCR Platform (Photo courtesy of Nanyang Technological University).
Alpha-Thalassemia is a group of recessively inherited hemoglobin (Hb) disorders that result from decreased or absent synthesis of α-globin chains, affecting up to 5% of the world's population, mainly prevalent in the Mediterranean coastal countries, Southeast Asia, some African countries, and southern China.
Thalassemia is a group of inherited blood disorders that reduces the ability of blood to circulate oxygen throughout the body. The severity can vary from benign to life threatening; therefore, it is important to identify infants as early as possible who may develop thalassemia-associated symptoms, as well as parents who are carriers. This requires the availability of practical and precise molecular diagnostic tools.
Scientists at the Southern Medical University (Guangzhou, China) developed a rapid, accurate novel assay for non-deletional alpha-thalassemia genotyping based on one-step nested asymmetric polymerase chain reaction (PCR) melting curve analysis, which may enhance prenatal diagnosis, newborn screening, and large-scale population screening. To assess the assay for mass screening, 1,250 blood samples referred to their laboratory for the molecular diagnosis of α-thalassemia were randomly selected. The genomic DNA (gDNA) samples were extracted from peripheral blood lymphocytes using TIANamp Blood DNA Kit (TianGen Biotech Co, Ltd, Beijing, China). The assay was a one-step closed-tube genotyping method that involved nested asymmetric PCR and melting curve analysis running on a Bio-Rad CFX96 Real-Time PCR Platform (Bio-Rad, Hercules, CA, USA).
The investigators tested the ability of the new assay to detect five non-deletional alpha-thalassemia mutations. All five mutations were accurately identified with a concordance rate of 100% in a blind analysis of 255 samples with known genotypes, as determined by other analytic methods including gap-PCR, PCR-reverse dot blot (RDB), or Sanger sequencing. The investigators also tested the capability of the new assay to screen large populations. After testing 1,250 blood samples, the assay showed 100% sensitivity and specificity for all of the targeted mutations. The overall analysis time with the new assay was just under 2.5 hours. This is considerably faster than other molecular genetic testing methods, such as Sanger sequencing, which require 380 minutes, or RDB, which takes 300 minutes.
Wanjun Zhou, PhD, a medical geneticist and senior author of the study, said, “These other methods are unsuitable for use in large-scale screening programs because they have limitations such as cumbersome operation, low throughput, subjective interpretation, and possible laboratory contamination caused by post-PCR open-tube operation. Our results prove that this new assay is accurate, reliable, simple, and rapid and can meet the requirements for clinical diagnosis and mass screening of non-deletional alpha-thalassemia”.
The authors concluded that an assay of nested asymmetric PCR melting analysis for rapid and accurate genotyping of non-deletional α-thalassemia has been established, including the mutations of WS (HBA2: c.369C>G), QS (HBA2: c.377T>C), CS (HBA2: c.427T>C), CD30 (HBA2: c.91_93delGAG), and CD31 (HBA2: c. 95G>A). Moreover, the strategy of this study can effectively overcome the bottleneck of high homology and GC-rich secondary structure. The study was published on May 29, 2020 in The Journal of Molecular Diagnostics.
Related Links:
Southern Medical University
TianGen Biotech Co
Thalassemia is a group of inherited blood disorders that reduces the ability of blood to circulate oxygen throughout the body. The severity can vary from benign to life threatening; therefore, it is important to identify infants as early as possible who may develop thalassemia-associated symptoms, as well as parents who are carriers. This requires the availability of practical and precise molecular diagnostic tools.
Scientists at the Southern Medical University (Guangzhou, China) developed a rapid, accurate novel assay for non-deletional alpha-thalassemia genotyping based on one-step nested asymmetric polymerase chain reaction (PCR) melting curve analysis, which may enhance prenatal diagnosis, newborn screening, and large-scale population screening. To assess the assay for mass screening, 1,250 blood samples referred to their laboratory for the molecular diagnosis of α-thalassemia were randomly selected. The genomic DNA (gDNA) samples were extracted from peripheral blood lymphocytes using TIANamp Blood DNA Kit (TianGen Biotech Co, Ltd, Beijing, China). The assay was a one-step closed-tube genotyping method that involved nested asymmetric PCR and melting curve analysis running on a Bio-Rad CFX96 Real-Time PCR Platform (Bio-Rad, Hercules, CA, USA).
The investigators tested the ability of the new assay to detect five non-deletional alpha-thalassemia mutations. All five mutations were accurately identified with a concordance rate of 100% in a blind analysis of 255 samples with known genotypes, as determined by other analytic methods including gap-PCR, PCR-reverse dot blot (RDB), or Sanger sequencing. The investigators also tested the capability of the new assay to screen large populations. After testing 1,250 blood samples, the assay showed 100% sensitivity and specificity for all of the targeted mutations. The overall analysis time with the new assay was just under 2.5 hours. This is considerably faster than other molecular genetic testing methods, such as Sanger sequencing, which require 380 minutes, or RDB, which takes 300 minutes.
Wanjun Zhou, PhD, a medical geneticist and senior author of the study, said, “These other methods are unsuitable for use in large-scale screening programs because they have limitations such as cumbersome operation, low throughput, subjective interpretation, and possible laboratory contamination caused by post-PCR open-tube operation. Our results prove that this new assay is accurate, reliable, simple, and rapid and can meet the requirements for clinical diagnosis and mass screening of non-deletional alpha-thalassemia”.
The authors concluded that an assay of nested asymmetric PCR melting analysis for rapid and accurate genotyping of non-deletional α-thalassemia has been established, including the mutations of WS (HBA2: c.369C>G), QS (HBA2: c.377T>C), CS (HBA2: c.427T>C), CD30 (HBA2: c.91_93delGAG), and CD31 (HBA2: c. 95G>A). Moreover, the strategy of this study can effectively overcome the bottleneck of high homology and GC-rich secondary structure. The study was published on May 29, 2020 in The Journal of Molecular Diagnostics.
Related Links:
Southern Medical University
TianGen Biotech Co
Latest Hematology News
- Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
- Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
- Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
- New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients
- Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers
- Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
- New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
- Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
- New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
- New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
- New Automated Hemostasis Systems Become Available Across US Laboratories
- Updated Ferritin Thresholds Improve Detection of Iron Deficiency
- Variation in AML Residual Disease Testing Prompts Push for Standardization
- Hidden Molecular Mechanism Behind HIT Blood-Clotting Disorder Revealed
- Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
- Biomarker-Guided Framework Aims to Guide Mantle Cell Lymphoma Therapy
Channels
Clinical Chemistry
view channel
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians
Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







